CHMA News and Press, Chiasma Inc. From 07/30/19

Chiasma Inc. ( CHMA ) shares rose over 30% recently, buoyed by favorable results from the Phase 3 clinical trial for its octreotide capsules, conditionally trade-named drug Mycapssa, for the maintenance treatment of adults with acromegaly. Acromegaly is a hormone disorder that typically de...

Chiasma (NASDAQ: CHMA ) prices its public offering of 10M common shares at $5.50 per share. Underwriters over-allotment is an additional 1.5M shares. Closing date is July 30. More news on: Chiasma, Inc., Healthcare stocks news, Stocks on the move, Read more ...

WALTHAM, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of its previously announced underwritten public offering ...

Gainers : Therapix Biosciences (NASDAQ: TRPX ) +45% . Chiasma (NASDAQ: CHMA ) +31% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +24% . Hoth Therapeutics (NASDAQ: HOTH ) +20% . Torchlight Energy Resources (NASDAQ: TRCH ) +17% . Realogy Holdings (NYSE: RLGY ) +16% . ClearSign Combustion...

Chiasma (NASDAQ: CHMA ) +21%  as Mycapssa successful in late-stage acromegaly study. More news on: Chiasma, Inc., Realogy Holdings Corp., Diffusion Pharmaceuticals Inc., Stocks on the move, Read more ...

Thinly traded micro cap Chiasma (NASDAQ: CHMA ) is up  30%  premarket on increased volume in response to positive results from a Phase 3 clinical trial, OPTIMAL , evaluating Mycapssa (octreotide) for the maintenance treatment of adults with acromegaly , a hormone disorder chara...

SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa who completed the 36-week study opted to continue into the Open Label Extension Company to host conference ca...

Editor's note: Seeking Alpha is proud to welcome Tungsten Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Technology ...

Chiasma CHMA has been selected for inclusion in Russell 3000 Index, effective after the US market opens on July 1 . More news on: Chiasma, Inc., Read more ...

In an update to investors, Chiasma (NASDAQ: CHMA ) announces that topline data from the Phase 3 OPTIMAL study evaluating Mycapssa (octreotide) in patients with acromegaly should be released by mid-Q3. More news on: Chiasma, Inc., Healthcare stocks news, Stocks on the move, Read mor...